Blockade of Cripto Binding to Cell Surface GRP78 Inhibits Oncogenic Cripto Signaling Via MAPK/PI3K and Smad2/3 Pathways
Overview
Affiliations
Cripto is a developmental oncoprotein that signals via mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Smad2/3 pathways. However, the molecular basis for Cripto coupling to these pathways during embryogenesis and tumorigenesis is not fully understood. In this regard, we recently demonstrated that Cripto forms a cell surface complex with the HSP70 family member glucose-regulated protein-78 (GRP78). Here, we provide novel functional evidence demonstrating that cell surface GRP78 is a necessary mediator of Cripto signaling in human tumor, mammary epithelial and embryonic stem cells. We show that targeted disruption of the cell surface Cripto/GRP78 complex using shRNAs or GRP78 immunoneutralization precludes Cripto activation of MAPK/PI3K pathways and modulation of activin-A, activin-B, Nodal and transforming growth factor-beta1 signaling. We further demonstrate that blockade of Cripto binding to cell surface GRP78 prevents Cripto from increasing cellular proliferation, downregulating E-Cadherin, decreasing cell adhesion and promoting pro-proliferative responses to activin-A and Nodal. Thus, disrupting the Cripto/GRP78 binding interface blocks oncogenic Cripto signaling and may have important therapeutic value in the treatment of cancer.
Regulation of Granzymes A and B by High-Risk HPV: Impact on Immune Evasion and Carcinogenesis.
Maleka M, Mbita Z, Morafo V Viruses. 2025; 17(2).
PMID: 40006976 PMC: 11861749. DOI: 10.3390/v17020221.
GRP78 in Glioma Progression and Therapy: Implications for Targeted Approaches.
Yang Y, Li W, Zhao Y, Sun M, Xing F, Yang J Biomedicines. 2025; 13(2).
PMID: 40002794 PMC: 11852679. DOI: 10.3390/biomedicines13020382.
Wei S, Fan X, Li X, Zhou W, Zhang Z, Dai S Adv Sci (Weinh). 2024; 12(4):e2406674.
PMID: 39629920 PMC: 11775527. DOI: 10.1002/advs.202406674.
Inhibin subunit beta B (INHBB): an emerging role in tumor progression.
Liu Y, Zhou Q, Zou G, Zhang W J Physiol Biochem. 2024; 80(4):775-793.
PMID: 39183219 DOI: 10.1007/s13105-024-01041-y.
Hu B, Liu G, Zhao K, Zhang G Front Oncol. 2024; 14:1388999.
PMID: 38646439 PMC: 11026673. DOI: 10.3389/fonc.2024.1388999.